302 related articles for article (PubMed ID: 32591352)
1. Analysis of real-world PD-L1 IHC 28-8 and 22C3 pharmDx assay utilisation, turnaround times and analytical concordance across multiple tumour types.
Krigsfeld GS; Prince EA; Pratt J; Chizhevsky V; William Ragheb J; Novotny J; Huron D
J Clin Pathol; 2020 Oct; 73(10):656-664. PubMed ID: 32591352
[TBL] [Abstract][Full Text] [Related]
2. Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms.
Ilie M; Khambata-Ford S; Copie-Bergman C; Huang L; Juco J; Hofman V; Hofman P
PLoS One; 2017; 12(8):e0183023. PubMed ID: 28797130
[TBL] [Abstract][Full Text] [Related]
3. Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma.
Zajac M; Scott M; Ratcliffe M; Scorer P; Barker C; Al-Masri H; Rebelatto MC; Walker J
Diagn Pathol; 2019 Sep; 14(1):99. PubMed ID: 31477145
[TBL] [Abstract][Full Text] [Related]
4. A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies.
Batenchuk C; Albitar M; Zerba K; Sudarsanam S; Chizhevsky V; Jin C; Burns V
J Clin Pathol; 2018 Dec; 71(12):1078-1083. PubMed ID: 30275099
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 testing of non-small cell lung cancer using different antibodies and platforms: a Swiss cross-validation study.
Savic S; Berezowska S; Eppenberger-Castori S; Cathomas G; Diebold J; Fleischmann A; Jochum W; Komminoth P; McKee T; Letovanec I; Jasarevic Z; Rössle M; Singer G; von Gunten M; Zettl A; Zweifel R; Soltermann A; Bubendorf L
Virchows Arch; 2019 Jul; 475(1):67-76. PubMed ID: 31127385
[TBL] [Abstract][Full Text] [Related]
6. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
Ilie M; Juco J; Huang L; Hofman V; Khambata-Ford S; Hofman P
Cancer Cytopathol; 2018 Apr; 126(4):264-274. PubMed ID: 29411536
[TBL] [Abstract][Full Text] [Related]
7. Equivalence of laboratory-developed test and PD-L1 IHC 22C3 pharmDx across all combined positive score indications.
Vainer G; Huang L; Emancipator K; Nuti S
PLoS One; 2023; 18(6):e0285764. PubMed ID: 37267266
[TBL] [Abstract][Full Text] [Related]
8. Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors.
Marchetti A; Barberis M; Franco R; De Luca G; Pace MV; Staibano S; Volante M; Buttitta F; Guerini-Rocco E; Righi L; D'antuono T; Scagliotti GV; Pinto C; De Rosa G; Papotti M
J Thorac Oncol; 2017 Nov; 12(11):1654-1663. PubMed ID: 28818609
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 expression in gastric cancer: interchangeability of 22C3 and 28-8 pharmDx assays for responses to immunotherapy.
Ahn S; Kim KM
Mod Pathol; 2021 Sep; 34(9):1719-1727. PubMed ID: 34002009
[TBL] [Abstract][Full Text] [Related]
10. Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.
Büttner R; Gosney JR; Skov BG; Adam J; Motoi N; Bloom KJ; Dietel M; Longshore JW; López-Ríos F; Penault-Llorca F; Viale G; Wotherspoon AC; Kerr KM; Tsao MS
J Clin Oncol; 2017 Dec; 35(34):3867-3876. PubMed ID: 29053400
[TBL] [Abstract][Full Text] [Related]
11. Comparison of three FDA-approved diagnostic immunohistochemistry assays of PD-L1 in triple-negative breast carcinoma.
Huang X; Ding Q; Guo H; Gong Y; Zhao J; Zhao M; Sui D; Wu Y; Chen H; Liu H; Zhang J; Resetkova E; Moulder SL; Wang WL; Huo L
Hum Pathol; 2021 Feb; 108():42-50. PubMed ID: 33221342
[TBL] [Abstract][Full Text] [Related]
12. Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab.
Eckstein M; Erben P; Kriegmair MC; Worst TS; Weiß CA; Wirtz RM; Wach S; Stoehr R; Sikic D; Geppert CI; Weyerer V; Bertz S; Breyer J; Otto W; Keck B; Burger M; Taubert H; Weichert W; Wullich B; Bolenz C; Hartmann A; Erlmeier F
Eur J Cancer; 2019 Jan; 106():234-243. PubMed ID: 30528808
[TBL] [Abstract][Full Text] [Related]
13. A Harmonization Study for the Use of 22C3 PD-L1 Immunohistochemical Staining on Ventana's Platform.
Neuman T; London M; Kania-Almog J; Litvin A; Zohar Y; Fridel L; Sandbank J; Barshak I; Vainer GW
J Thorac Oncol; 2016 Nov; 11(11):1863-1868. PubMed ID: 27664534
[TBL] [Abstract][Full Text] [Related]
14. SP142 PD-L1 Scoring Shows High Interobserver and Intraobserver Agreement in Triple-negative Breast Carcinoma But Overall Low Percentage Agreement With Other PD-L1 Clones SP263 and 22C3.
Pang JB; Castles B; Byrne DJ; Button P; Hendry S; Lakhani SR; Sivasubramaniam V; Cooper WA; Armes J; Millar EKA; Raymond W; Roberts-Thomson S; Kumar B; Burr M; Selinger C; Harvey K; Chan C; Beith J; Clouston D; O'Toole SA; Fox SB;
Am J Surg Pathol; 2021 Aug; 45(8):1108-1117. PubMed ID: 34232604
[TBL] [Abstract][Full Text] [Related]
15. Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types.
Maule JG; Clinton LK; Graf RP; Xiao J; Oxnard GR; Ross JS; Huang RSP
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36302564
[TBL] [Abstract][Full Text] [Related]
16. Evaluating programmed death-ligand 1 (PD-L1) in head and neck squamous cell carcinoma: concordance between the 22C3 PharmDx assay and the SP263 assay on whole sections from a multicentre study.
Cerbelli B; Girolami I; Eccher A; Costarelli L; Taccogna S; Scialpi R; Benevolo M; Lucante T; Luigi Alò P; Stella F; Gemma Pignataro M; Fadda G; Perrone G; D'Amati G; Martini M
Histopathology; 2022 Jan; 80(2):397-406. PubMed ID: 34496080
[TBL] [Abstract][Full Text] [Related]
17. RUSSCO-RSP comparative study of immunohistochemistry diagnostic assays for PD-L1 expression in urothelial bladder cancer.
Zavalishina L; Tsimafeyeu I; Povilaitite P; Raskin G; Andreeva Y; Petrov A; Kharitonova E; Rumyantsev A; Pugach I; Frank G; Tjulandin S
Virchows Arch; 2018 Dec; 473(6):719-724. PubMed ID: 30209552
[TBL] [Abstract][Full Text] [Related]
18. Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer.
Scheel AH; Baenfer G; Baretton G; Dietel M; Diezko R; Henkel T; Heukamp LC; Jasani B; Jöhrens K; Kirchner T; Lasitschka F; Petersen I; Reu S; Schildhaus HU; Schirmacher P; Schwamborn K; Sommer U; Stoss O; Tiemann M; Warth A; Weichert W; Wolf J; Büttner R; Rüschoff J
Histopathology; 2018 Feb; 72(3):449-459. PubMed ID: 28851100
[TBL] [Abstract][Full Text] [Related]
19. Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial.
Gadgeel S; Hirsch FR; Kerr K; Barlesi F; Park K; Rittmeyer A; Zou W; Bhatia N; Koeppen H; Paul SM; Shames D; Yi J; Matheny C; Ballinger M; McCleland M; Gandara DR
Clin Lung Cancer; 2022 Jan; 23(1):21-33. PubMed ID: 34226144
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma.
Hodgson A; Slodkowska E; Jungbluth A; Liu SK; Vesprini D; Enepekides D; Higgins K; Katabi N; Xu B; Downes MR
Am J Surg Pathol; 2018 Aug; 42(8):1059-1066. PubMed ID: 29750666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
